Literature DB >> 7553988

Pharmaceutical characterization of commercially available intravenous fat emulsions: estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy.

H Komatsu1, A Kitajima, S Okada.   

Abstract

Particle profiles such as the average diameter, size distribution and dispersion, as well as the zeta potential, of commercially available intravenous fat emulsions of high-calorie nutrient fluids (6 products) and drug carriers (4 products) were examined using photon correlation spectroscopy (dynamic light scattering). Wide variations were observed in number-weighted (dn), weight-weighted (dw) and z-average diameters, and dw/dn ratios as a measure of polydispersity. Average size is not sufficient for the pharmaceutical characterization of particles and the determination of size distribution or dw/dn value is essential for more precise information. Although measuring the zeta potential of fat emulsions is of considerable value in estimating their stability on long-term storage, a medium which accurately reflects the environment of the droplets in the system of interest should be chosen when diluting the emulsion.

Mesh:

Substances:

Year:  1995        PMID: 7553988     DOI: 10.1248/cpb.43.1412

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  13 in total

1.  Influence of incorporation methods on partitioning behavior of lipophilic drugs into various phases of a parenteral lipid emulsion.

Authors:  Warisada Sila-on; Nontima Vardhanabhuti; Boonsri Ongpipattanakul; Poj Kulvanich
Journal:  AAPS PharmSciTech       Date:  2008-05-22       Impact factor: 3.246

2.  Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line.

Authors:  Niladri Chattopadhyay; Jason Zastre; Ho-Lun Wong; Xiao Yu Wu; Reina Bendayan
Journal:  Pharm Res       Date:  2008-05-31       Impact factor: 4.200

3.  Formulation and evaluation of carnosic acid nanoparticulate system for upregulation of neurotrophins in the brain upon intranasal administration.

Authors:  Siva Ram Kiran Vaka; H N Shivakumar; Michael A Repka; S Narasimha Murthy
Journal:  J Drug Target       Date:  2012-10-01       Impact factor: 5.121

4.  Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells.

Authors:  Xiao Gu; Wenli Zhang; Jianping Liu; John P Shaw; Yuanjun Shen; Yiming Xu; Hui Lu; Zimei Wu
Journal:  AAPS PharmSciTech       Date:  2011-09-17       Impact factor: 3.246

5.  Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility.

Authors:  Rui-ling Duan; Xun Sun; Jie Liu; Tao Gong; Zhi-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-12-20       Impact factor: 6.150

6.  Lipid effects on expulsion rate of amphotericin B from solid lipid nanoparticles.

Authors:  See Wei Tan; Nashiru Billa
Journal:  AAPS PharmSciTech       Date:  2013-12-07       Impact factor: 3.246

7.  Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers.

Authors:  Jun Zhou; Daxin Zhou
Journal:  Drug Des Devel Ther       Date:  2015-09-18       Impact factor: 4.162

8.  Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability.

Authors:  Ana Rute Neves; Marlene Lúcio; Susana Martins; José Luís Costa Lima; Salette Reis
Journal:  Int J Nanomedicine       Date:  2013-01-07

9.  Solid lipid nanoparticles of a water soluble drug, ciprofloxacin hydrochloride.

Authors:  M Shah; Y K Agrawal; K Garala; A Ramkishan
Journal:  Indian J Pharm Sci       Date:  2012-09       Impact factor: 0.975

10.  CONTINUOUS PRODUCTION OF RALOXIFENE HYDROCHLORIDE LOADED NANOSTRUCTURED LIPID CARRIERS USING HOT-MELT EXTRUSION TECHNOLOGY.

Authors:  Derick Muhindo; Eman A Ashour; Mashan Almutairi; Poorva H Joshi; Michael A Repka
Journal:  J Drug Deliv Sci Technol       Date:  2021-07-05       Impact factor: 5.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.